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INTRODUCTION
Since the advent of widespread Papanicolaou 
(PAP) smear screening in the United States during 
the 1950s, incidence and mortality rates of invasive 
cervical cancer dramatically decreased by more than 
70%. Worldwide, it is the second leading cause of 
cancer death in women. PAP test collects exfoliated 
cells from the surface of the cervix (10). Exfoliation 
occurs from most normal, precancerous, and 
cancerous cervical epithelium. It is the detection 
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of precancerous cells that predates invasive disease 
by years and allows for cancer prevention. PAP 
test evolution is instructive in many aspects. First 
devised as a simple method to determine the 
reproductive cycle of laboratory animals by George 
Papanicolaou, it has evolved into a source of cellular 
material for sophisticated molecular and diagnostic 
techniques. Although apparently ever changing, 
the one consistent aspect of its past and future 
is the success that PAP screening has had in the 
prevention of invasive cervical cancer. Terminology 
was developed for squamous preinvasive disease 
and reflected its origin in the cervical epithelium. 
Cervical cancer is caused by a sexually transmitted 
disease, human papillomavirus (HPV) infection 
of the cervix. HPV infection is common among 
females, and some studies suggest that more than 
70% of women will have had an infection by the end 
of their sexual experience. Infection with a high-
risk type of HPV is a requisite for development 
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of preinvasive and invasive squamous neoplasia 
of the cervix. Other risk factors include multiple 
sexual partners, intercourse at an early age, poor 
individual’s hygiene, immunocompromises, other 
sexually transmitted diseases such as herpes simplex 
virus type and cigarette smoking (1,11). Liquid-based 
PAP test is another method developed to improve 
the preservation and presentation of cells for cervical 
cytologic analysis. Basic technique of the method is 
shown on Fig. 1. 
This method is more sensitive in detecting the 
cervical lesions than the conventional technique. It 
allows for the cellular material to be deposited in a 
liquid preservative that rinses the collection device, 
filters blood and mucus and fixes the cells.
MATERIAL AND METHOD
In the Department of Obstetrics and Gynecology, 
Medical University of Varna, we examined 100 
female patients by using LBC screening method for 
the purpose of detecting early cervical lesions. We 
compared the results from LBC with those from 
conventional PAP smear widely used in Bulgaria 
concerning different criteria. Besides we tested the 
practicability of this new method in Bulgaria c and 
as well as to test LBC practicability. Our results were 
compared with those published by foreign authors, 
mainly from the USA, Australia and Scandinavian 
countries. The unit used for preparation of the 
samples was ThinPrep2000. After undergoing 
standard procedures of fixation, we stained the 
slides after Romanovsky-Gimza method. The final 
slides were histologically evaluated. Bethesda System 
classification was applied for each histological 
result - Atypical squamous cells of undetermined 
significance (ASCUS), LSIL, high-grade squamous 
intraepithelial lesion (HSIL), and negative for 
intraepithelial lesion or malignancy (NILM) (13).
RESULTS
Our results show a reduction by 67% of the 
unsatisfactory and by 15% of ASCUS rates compared 
to conventional PAP slides. LSIL detection is by 
three times higher than conventional PAP test, too. 
There is a higher detection rate of invasive cancer 
cases. However, taking into considerations the small 
number of invasive cancer patients, further tests 
need to be performed to evaluate the actual benefits 
of LBC over conventional PAP test. 
There are significant advantages of LBC mainly 
due to the lower number of unsatisfactory results and 
higher specificity for LSIL. Liquid-based collection 
and processing provide more representative cervical 
sampling than conventional smearing of the specimen 
on a glass slide. When a conventional PAP smear test 
is collected, over 80% of the cells collected on the 
sampling device are not transferred to the slide. So, 
existing cervical cell abnormalities could be on the 
collection device after the sample is collected from 
Fig. 1. Basic technique of liquid-based cytology
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the patient. However, they might never occur on the 
slide for diagnostic observation. The slide received 
will have missing cells and obscuring elements that 
limit diagnosis accuracy. This can cause a non-
representative sample that may not reflect patient’s 
actual pathological condition. 
When using the ThinPrep LBC PAP test, 
virtually, 100% of cells collected in the sample device 
are transferred to the ThinPrep vial. The specimen 
is then sent to the laboratory, where an automated 
processor prepares the slide by dispersing and 
filtering the sample and then placing a representative 
sample on the slide. The process ensures that a 
representative portion of the patient,s sample is 
placed on the microscope slide while reducing thhe 
obscuring blood, mucus, and non-diagnostic debris 
(2,12). At the laboratory, the LBC System addresses 
screening errors, a main cause of false-negative 
results. Using the conventional method, a physician 
smears the sample collected from the patient onto a 
slide. This sample is commonly clouded with mucus 
and debris. When combined with a slide containing 
cells that are overlapping and clumped together, this 
results in a slide that is exceptionally difficult to read. 
With LBC, the physician needs only to send the vial 
containing the cell sample to the laboratory. There, 
a clear, easy-to-read slide sample that displays a thin 
layer of evenly distributed cells is produced (5-7).
Since FDA approval in 1996, more than 170 
studies have been published in peer-reviewed medical 
journals, demonstrating the superiority of the LBC 
Pap Test in a clinical setting. Compared to foreign 
results our results demonstrate the same tendencies 
and values (3,4,9). An Australian meta-analysis of 
LBC compared to conventional cytology is presented 
in Table 1. 
DISCUSSION
The ThinPrep LBC test is the only PPAP test 
approved by the FDA as ‘significantly more effective’ 
than the conventional PAP smear for detection of 
cervical abnormalities. According to some studies, 
the ThinPrep LBC test improves the detection of 
precancerous cervical cells when compared with the 
conventional PAP smear. In the USA, more than 87% 
of the screening is performed by LBC. The ThinPrep 
LBC test possessees certificates of approval from the 
FDA and the European CE. It is the most widely used 
liquid-based PAP test as well in Ireland, Germany, 
and the UK. Nowadays it is applied in many other 
European countries as well as in Israel, Jordan and 
India. It allows for multiple observation of the vial 
and other testing procedures such as HPV and 
Chlamydia testing (8).
CONCLUSION
Taking into consideration the obvious benefits 
and ‘easy-to-perform’ technique of the LBC, the 
huge experience of foreign countries in using this 
revolutionary and proven method for screening 
for cervical lesions as well as our initial practical 
experience gained in the Department of Obstetrics 
and Gynecology, Medical University of Varna we 
could draw the following conclusions:
Diagnostic categories
Conventional cytology Liquid-based cytology
n=688,035 n=562,662
n % n %
normal 646,014 93,89 518,878 92,22
ASCUS 26,561 3,86 22,986 4,09
LSIL 10,236 1,49 15,041 2,67
HSIL 4,771 0,69 5,348 0,95
cancer 453 0,07 409 0,07
Table 1. Comparative values of diagnostic categories by using conventional and liquid-based cytology
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1. LBC should be offered as a screening option 
to more patients in Bulgaria.
2. Bulgarian hospitals should routinely use LBC 
for cervical cancer screening.
3. Bulgarian pathologists should use Bethesda 
System classification as a main guideline 
during the histological evaluation of the 
cervical slides.
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